NMRA Confirms No Substandard Immunoglobulin in Use at State Hospitals

The National Medicines Regulatory Authority (NMRA) has clarified that immunoglobulin currently in use at government hospitals is safe and meets all quality standards, dismissing recent media claims suggesting otherwise.

NMRA Chairman Dr. Ananda Wijewickrema stated that the product in question, manufactured by ICHOR Biologics Pvt. Ltd. in India, was approved in 2023.

He acknowledged that the medicine was temporarily withheld from distribution following a complaint and preliminary concerns during testing.

However, further analysis—including tests conducted by India’s Central Drugs Standard Control Organisation—confirmed that the immunoglobulin met all required standards. Following this, a special technical committee of medical specialists reviewed the findings and approved its continued use.

Dr. Wijewickrema assured the public that the product has undergone thorough evaluations and stressed that there is no reason to question its quality.

Leave a Reply

Your email address will not be published. Required fields are marked *

You cannot copy content of this page